Tevogen Bio (NASDAQ:TVGN) Announces Earnings Results
by Renee Jackson · The Cerbat GemTevogen Bio (NASDAQ:TVGN – Get Free Report) issued its earnings results on Friday. The company reported ($1.52) earnings per share for the quarter, topping the consensus estimate of ($2.53) by $1.01, FiscalAI reports.
Tevogen Bio Trading Up 4.6%
TVGN traded up $0.30 during trading on Friday, hitting $6.87. The stock had a trading volume of 8,215 shares, compared to its average volume of 25,368. Tevogen Bio has a 12 month low of $3.64 and a 12 month high of $49.50. The company has a 50 day simple moving average of $7.02 and a 200-day simple moving average of $8.34. The firm has a market cap of $28.99 million, a PE ratio of -1.49 and a beta of 0.18.
Institutional Trading of Tevogen Bio
Hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. lifted its holdings in shares of Tevogen Bio by 126.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after buying an additional 152,572 shares during the last quarter. Bridgeway Capital Management LLC grew its position in Tevogen Bio by 66.7% during the third quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock worth $65,000 after buying an additional 33,000 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in Tevogen Bio by 304.1% during the fourth quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after acquiring an additional 130,738 shares during the period.
Analysts Set New Price Targets
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Tevogen Bio in a research report on Friday, July 17th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Tevogen Bio has a consensus rating of “Reduce” and a consensus target price of $100.00.
Read Our Latest Report on TVGN
Tevogen Bio Company Profile
Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).
In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.